HOME2019-03-11T17:27:49+01:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

PI Olga Corti, ICM acknowledges PD-MitoQUANT at two conferences

September 25th, 2019|

Institut du Cerveau et de la Moelle Epinière (ICM) PI Dr Olga Corti presented her work and acknowledged PD-MitoQUANT at two recent conferences. The first conference presentation was on September 3, 2019, at the 23rd Biennial ESN meeting in Milan. Olga's talk was titled: “From dysfunction of PINK1/Parkin-mediated mitochondrial quality [...]

PD-MitoQUANT ICM PIs co-author paper in Scientific Reports

September 23rd, 2019|

PD-MitoQUANT partners at Institut du Cerveau et de la Moelle Epinière recently co-authored a study entitled "The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells." in Scientific Reports on August 14, 2019. This work was undertaken by M. Jacoupy, E. Hamon-Keromen, A.Ordureau, Z. Erpapazoglou, F. [...]

Read more